drugset / Trial / NCT04564053

Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants

NCT04564053

Phase 1 Completed 12 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study was to determine the safety, tolerability and pharmacokinetics after single ascending dose of LNA043 in Japanese participants with osteoarthritis of the knee.

Timeline

Start
2020-09-23
Primary completion
2020-12-10
Completion
2020-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject LNA043 Unknown Other

Indications